AA
KYMR icon

ALPS Advisors’s Kymera Therapeutics KYMR Stock Holding History

ALPS Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-66,457
Closed -$5.54M – 1198
2026
Q1 		$5.54M Buy
66,457
+1,734
+3% +$137K 0.03% 235
2025
Q4 		$5.04M Buy
+64,723
New +$4.37M 0.03% 246

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

ALPS Advisors's KYMR Position: Q2 2026 in Review

ALPS Advisors sold out of Kymera Therapeutics (KYMR) in Q2 2026, closing a stake of 66,457 shares — an estimated $5.54M sold.

ALPS Advisors first reported a position in KYMR in Q4 2025 and held it in 2 quarters. The position peaked at $5.54M in Q1 2026. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • ALPS Advisors reported no remaining Kymera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • ALPS Advisors sold 66,457 Kymera Therapeutics shares in Q2 2026, an estimated $5.54M.
  • ALPS Advisors first reported a position in Kymera Therapeutics in Q4 2025 and held it in 2 quarters.
  • ALPS Advisors's Kymera Therapeutics position peaked at $5.54M in Q1 2026.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.